STAT2 and hepatocellular carcinoma: STAT3 gene is highly expressed in hepatocellular carcinoma cells, and regorafenib (Stivarga), a drug targeting STAT2 for the treatment of hepatocellular carcinoma, has been identified as a second-line oral agent (Jindal et al., 2019).